MAIA Biotechnology (MAIA) Cash & Current Investments (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Cash & Current Investments for 6 consecutive years, with $34.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 216.78% year-over-year to $34.4 million; the TTM figure through Mar 2026 stood at $34.4 million (up 216.78% YoY), while the FY2025 annual figure was $8.7 million, down 9.82% from the prior year.
• Cash & Current Investments climbed to $34.4 million in Q1 2026 per MAIA's latest filing, from $8.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $34.4 million in Q1 2026 and bottomed at $6.1 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $11.0 million across 5 years, with a median of $9.4 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Current Investments sank 56.59% — and 2026, when it surged 216.78%.
• MAIA Biotechnology's Cash & Current Investments stood at $11.0 million in 2022, then sank by 34.7% to $7.2 million in 2023, then surged by 34.27% to $9.6 million in 2024, then retreated by 9.82% to $8.7 million in 2025, then soared by 297.47% to $34.4 million in 2026.
• Business Quant data shows MAIA's Cash & Current Investments at $34.4 million in Q1 2026, $8.7 million in Q4 2025, and $10.9 million in Q3 2025.